David M Jackson PhD is an experienced executive focused on the development and commercialization of innovative healthcare technologies with an emphasis on paradigm changing products addressing unmet medical needs. David received his Doctorate in the medical sciences from the Boston University School of Medicine. David has authored several peer-reviewed papers and holds several patents and patents pending. Several products from his work have reached market or are currently undergoing clinical trials. He is also trained as a Patent Agent and previously held several SEC licenses. Since 2020 David has been CEO of Ceria Therapeutics Inc, a platform biopharma company developing multiple assets directed to life-threatening and debilitating conditions related to excessive cytokine production. He has previously served as CEO of Neuraptive Therapeutics Inc, Darwin Bio LLC, and Spinomix SA; as well as several other senior management and Board positions; multiple engagements with regulatory agencies leading product development efforts; the raising of >$100M in capital from investors and non-dilutive funding sources; and key roles in several exits.